Key Takeaways
- Resilient quarter, pricing headwinds persist: Custom Synthesis grew to 53% of revenue (vs 47% generics), but generic pricing pressure and logistics costs continue to weigh on margins.
- Kakinada Unit 3 is live and strategic: Operational since January 2025, it has freed up GMP space at older units by absorbing key starting material production, a move management calls essential for immediate growth.
- Peptide capacity is the big bet, but details are scarce: Newly commissioned Solid Phase Peptide Synthesis capacity has drawn strong innovator interest, yet management declined to quantify capacity, margins, or timelines, citing confidentiality agreements.
- Three dedicated custom synthesis units anchor the capex story: Backed by long-term volume commitments, these projects drive the ₹2,000 crore FY26 capex plan and will commercialize over the next 12 months.
- What to watch next quarter: Whether generic pricing stabilizes as management hopes, any regulatory progress on peptide commercialization, and the pace at which freed-up GMP capacity converts to revenue.
Custom Synthesis: The Growth Engine
- Mix shift in motion: Custom synthesis contributed 53% of revenue this quarter, up from a preferred 50/50 split with generics, reflecting lumpy project timing and strong innovator demand. Management wants the full-year mix at 50% each.
- Pipeline depth: Multiple active projects are progressing through R&D, pilot, and validation stages, with several expected to transition to commercial scale within 12 to 24 months. A healthy flow of RFPs and customer site visits supports the outlook.
- Three dedicated units: These large projects, disclosed to stock exchanges, carry long-term supply contracts with volume commitments and will commercialize over the next 12-month odd period. Management declined to discuss asset turnover or product mix, citing CDAs.
- Technology as differentiator: Advanced platforms in flow chemistry, biocatalysis, and green chemistry are now offered to global partners. The biocatalysis platform is at pilot scale with a few innovators, though management declined to say whether it signals an entry into biologics manufacturing.
Dr. Kiran S. Divi: "So right now, strategically, what we have done is, we have emptied Unit 1 and Unit 2 with all the key starting materials and moved it to Kakinada Unit 3, so that we have GMP space immediately available for our immediate growth."
Kakinada Unit 3: Capacity Unlocked, Revenue Delayed
- Operational since January 2025: Phase 1 assets worth ₹114 crores were capitalized during Q1 FY26. The facility is already contributing meaningfully to production and strengthening backward integration.
- The strategic swap: Key starting materials previously made in Unit 1 and Unit 2 have been moved to Kakinada, freeing up GMP space for immediate growth opportunities. This is the near-term payoff from the facility.
- The long game: Forward-looking products with patents expiring much later are being qualified in Kakinada, but regulatory approvals will take at least 1 to 2 years. Until then, the facility works on backward integration.
- Capacity utilization steady at 80%: Even with Kakinada's additional capacity coming online, utilization held at 80%, a level management considers ideal for the organization.
- Revenue conversion lag: The freed-up GMP capacity at Units 1 and 2 still needs qualifications, validations, and regulatory approvals before revenues materialize. Operating leverage depends entirely on the pace of these approvals.
Dr. Kiran S. Divi: "While that is being done, certain long forward-looking products, which are getting off patent much later, we are qualifying them in Kakinada and then we will start the process, which will take at least 1 to 2 years before we have regulatory approvals in place for Kakinada."
Peptides & New Capabilities
- SPPS capacity commissioned: New Solid Phase Peptide Synthesis capacity has garnered strong interest from large pharma companies, particularly those developing GLP-1-based treatments. The pilot scale included a few 500 KL SPPS units, with larger commercial-scale capacity procured based on customer requirements.
- Commercialization timeline is aspirational: Management's wishful thinking is 12 to 14 months for commercialization, but this depends entirely on regulatory approvals and the innovator's own product timeline. Six months ago, the expectation was 18 to 24 months, so the outlook has shortened slightly.
- Details locked behind CDAs: Management declined to disclose capacity volumes, target markets, gross margin accretion, plant locations, or the number of partners, citing confidentiality agreements with innovators. When asked about major players, the response was "you can assume that."
- Gadolinium contrast media: Hopeful for sooner qualification than previously thought; six months ago the timeline was roughly 18 to 24 months, and management now hopes validations happen faster.
Dr. Kiran S. Divi: "I would -- again, our wishful thinking is 12 to 14 months. It all depends on the regulatory approvals. And then, I mean, we being a part of the innovator, it's based on his time line on getting the product commercialized."
Generics: Pricing Pressure and Portfolio Resilience
- Pricing headwinds persist: Generic pricing pressure stems from geopolitical instability and broad-based market corrections. Management does not see manufacturing becoming unviable for Divi's, but acknowledges the market must stabilize at some point because several corrections have to take place.
- Margin impact: Backward integration is reflected in gross margins, but pricing pressure in generics, plus additional costs from logistics, Red Sea shipping disruptions, and geopolitical issues, continue to weigh on the generic business more than custom synthesis.
- New product pipeline advancing: DMFs have been filed and validations completed for products including Brivaracetam and Ticagrelor, with commercial volumes expected to start moving in the next 6 to 12 months, pending customer approvals.
- Raw material stability: Prices remained stable through the quarter with healthy availability, supported by proactive safety stocks and a diversified sourcing mix. Inventory levels are broadly consistent with historical norms, though the company is moving toward leaner just-in-time models while maintaining prudent buffers.
Nilima Prasad Divi: "We are hoping that they would stabilize over the next few quarters."
Margins, Costs & Operating Model
- Gross margin under dual pressure: Backward integration benefits are offset by generic pricing pressure and elevated logistics costs tied to Red Sea disruptions and geopolitical factors. The custom synthesis business is less affected by these headwinds than generics.
- Green chemistry embedded in operations: The company looks at atom-to-atom efficiency and analyzes every mole of waste produced, driving yield improvements, capacity gains, and better product quality. This has become part of the organizational DNA over the last few years.
- Nutraceutical recovery underway: The business saw a post-COVID dip in multivitamins and related segments but is now seeing steady improvement and a steady rise. Capacity will be increased as and when required.
- Tariff uncertainty unquantified: Management called it too early to assume any effect, citing long-term customer relationships and the absence of clear methodology on whether tariffs apply to intermediates or APIs. No guidance was offered.
Dr. Kiran S. Divi: "And this has become a part of our DNA where we look at atom-to-atom efficiency and try to understand every mole of waste that we produce, on why the byproducts are being produced, thereby increasing our yield, capacity and better product."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Capex spend | ₹2,000 crores directed at strategic projects, capacity expansion, and technology upgrades | FY26 |
| Custom synthesis pipeline conversion | Several active projects transition to commercial scale | Next 12 to 24 months |
| Three dedicated CS units commercialization | Projects backed by long-term volume commitments go live | Next 12-month odd period |
| Generic product pipeline | Brivaracetam, Ticagrelor and others begin commercial volumes | Next 6 to 12 months |
| Kakinada regulatory approvals | GMP approvals for forward-looking products qualified at Unit 3 | At least 1 to 2 years |
| Generic/Custom Synthesis mix | Maintain at 50% each for the full year | FY26 |
| Pricing pressure stabilization | Hoping pressures stabilize | Next few quarters |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Consolidated total income | ₹2,529 cr, vs ₹2,197 cr in Q1 FY25 |
| Standalone total income | ₹2,476 cr, vs ₹2,142 cr in Q1 FY25 |
| Consolidated profit before tax | ₹733 cr, vs ₹604 cr in Q1 FY25 |
| Consolidated profit after tax | ₹545 cr, vs ₹430 cr in Q1 FY25 |
| Standalone profit before tax | ₹747 cr, vs ₹603 cr in Q1 FY25 |
| Standalone profit after tax | ₹557 cr, vs ₹430 cr in Q1 FY25 |
| Material consumption | ~40% of sales revenue, flat YoY |
| Constant currency growth | 14% |
| Forex gain | ₹39 cr gain, vs ₹1 cr loss in Q1 FY25 |
| Exports share | 88% of total income; Europe 58%, US 14% |
| Product mix | Generics 47%, Custom Synthesis 53% |
| Nutraceutical business revenue | ₹250 cr, vs ₹178 cr in Q1 FY25 |
| Capacity utilization | 80%, consistent over the last 1 year |
| Estimated capex for FY26 | ₹2,000 cr |
| Assets capitalized during the quarter | ₹261 cr, of which Kakinada Phase 1: ₹114 cr |
| Capital work in progress | ₹1,319 cr at quarter end |
| Cash on books | ₹4,205 cr at quarter end |
| Receivables | ₹2,521 cr at quarter end |
| Inventory | ₹3,087 cr at quarter end |